EICHOR
● Active Not Recruiting
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Metastatic Pancreatic Ductal Adenocarcinoma · Sponsor: Arcus Biosciences, Inc.
About this study
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (111)
| Research Site | Phoenix, Arizona, United States | — |
| Research Site | Tucson, Arizona, United States | — |
| Research Site | La Jolla, California, United States | — |
| Research Site | Los Alamitos, California, United States | — |
| Research Site | Los Angeles, California, United States | — |
| Research Site | Roseville, California, United States | — |
| Research Site | San Francisco, California, United States | — |
| Research Site | Santa Monica, California, United States | — |
| Research Site | Denver, Colorado, United States | — |
| Research Site | New Haven, Connecticut, United States | — |
| Research Site | Jacksonville, Florida, United States | — |
| Research Site | Miami, Florida, United States | — |
+ 99 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06608927